Year: 2022

logo250

Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence

YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential YH003 in combination with PD-1 are being dosed in...

Biocytogen27s_LOGO

Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence

YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential. YH003 in combination with PD-1 are being dosed in...

ORUM2BLOGO2B-2BPNG

Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors

ORM-5029 is a first-in-class drug candidate designed to selectively deliver catalytic GSPT1 protein degraders to HER2-expressing tumor cells via antibody...